CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
crc-research
A collection of 723 issues
CRC Research Finding
Skip to content
The CRC Digest
▪ Younger individuals with family history show increased advanced adenoma risk
Study of 409 patients undergoing early screening colonoscopy due to first-degree relative with advanced polyps found increased prevalence of advanced adenomas in younger individuals, supporting current early screening guidelines. (Gastroenterology and Hepatology Advances)
This
CRC Research Update — June 01, 2026
Today's colorectal cancer research highlights
BRAF V600E triplet regimen advances in phase 3 trial
Skip to content
The CRC Digest
BRAF V600E triplet regimen advances in phase 3 trial
BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology)
This content
CRC Research Finding
Skip to content
The CRC Digest
▪ Screening test preferences vary by sociodemographic factors in underserved populations
A survey of 1,014 adults aged 45-75 across community health centers found that preferences for stool test, blood test, and colonoscopy varied by sociodemographic factors and health beliefs, highlighting the need to understand
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases
Skip to content
The CRC Digest
◆ TRIAL DATA
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine
A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.
Phase 2 study combines pembrolizumab with chemotherapy in MSS CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase 2 study combines pembrolizumab with chemotherapy in MSS CRC — Clinical Colorectal Cancer
A phase 2 study evaluated pembrolizumab (an immunotherapy) combined with capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer. This combination approach aims to overcome
AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer — Clinical Colorectal Cancer
AZUR-4 is a phase 2, open-label, randomized study comparing neoadjuvant (before surgery) dostarlimab plus CAPEOX chemotherapy versus CAPEOX alone in previously untreated stage III or high-risk stage II mismatch
Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology
A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS